Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Sara Nysom Christiansen; Simon Horskjær Rasmussen; Mikkel Ostergaard; Marion Pons; Brigitte Michelsen; Karel Pavelka; Catalin Codreanu; Adrian Ciurea; Bente Glintborg; Maria Jose Santos; Ismail Sari; Ziga Rotar; Bjorn Gudbjornsson; Gary J. Macfarlane; Heikki Relas; Florenzo Iannone; Karin Laas; Johan K. Wallman; Marleen van de Sande; Sella Aarrestad Provan; Isabel Castrejon; Jakub Zavada; Corina Mogosan; Michael J. Nissen; Anne Gitte Loft; Anabela Barcelos; Yesim Erez; Katja Perdan Pirkmajer; Gerdur Grondal; Gareth T. Jones; Anna Mari Hokkanen; Maria Sole Chimenti; Sigrid Vorobjov; Daniela Di Giuseppe; Tore K. Kvien; Lucia Otero-Varela; Irene van der Horst-Bruinsma; Merete Lund Hetland; Lykke Midtbøll Ørnbjerg

doi:10.1136/rmdopen-2024-004166

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Karel Pavelka, Catalin Codreanu, Adrian Ciurea, Bente Glintborg, Maria Jose Santos, Ismail Sari, Ziga Rotar, Bjorn Gudbjornsson, Gary J. Macfarlane, Heikki Relas, Florenzo Iannone, Karin Laas, Johan K. Wallman, Marleen van de Sande, Sella Aarrestad ProvanIsabel Castrejon, Jakub Zavada, Corina Mogosan, Michael J. Nissen, Anne Gitte Loft, Anabela Barcelos, Yesim Erez, Katja Perdan Pirkmajer, Gerdur Grondal, Gareth T. Jones, Anna Mari Hokkanen, Maria Sole Chimenti, Sigrid Vorobjov, Daniela Di Giuseppe, Tore K. Kvien, Lucia Otero-Varela, Irene van der Horst-Bruinsma, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

5 Downloads (Pure)

Abstract

Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

Original language	English
Article number	e004166
Journal	RMD Open
Volume	10
Issue number	3
DOIs	https://doi.org/10.1136/rmdopen-2024-004166
Publication status	Published - 24 Jul 2024

Keywords

Ankylosing
Epidemiology
Pain
Patient Reported Outcome Measures
Spondylitis
Therapeutics

Access to Document

10.1136/rmdopen-2024-004166

e004166.fullFinal published version, 1.52 MBLicence: CC BY

Cite this

Christiansen, S. N., Rasmussen, S. H., Ostergaard, M., Pons, M., Michelsen, B., Pavelka, K., Codreanu, C., Ciurea, A., Glintborg, B., Santos, M. J., Sari, I., Rotar, Z., Gudbjornsson, B., Macfarlane, G. J., Relas, H., Iannone, F., Laas, K., Wallman, J. K., van de Sande, M., ... Ørnbjerg, L. M. (2024). Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study. RMD Open, 10(3), Article e004166. https://doi.org/10.1136/rmdopen-2024-004166

@article{ab927d98af434124915130bb6219cfce,

title = "Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study",

abstract = "Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.",

keywords = "Ankylosing, Epidemiology, Pain, Patient Reported Outcome Measures, Spondylitis, Therapeutics",

author = "Christiansen, {Sara Nysom} and Rasmussen, {Simon Horskj{\ae}r} and Mikkel Ostergaard and Marion Pons and Brigitte Michelsen and Karel Pavelka and Catalin Codreanu and Adrian Ciurea and Bente Glintborg and Santos, {Maria Jose} and Ismail Sari and Ziga Rotar and Bjorn Gudbjornsson and Macfarlane, {Gary J.} and Heikki Relas and Florenzo Iannone and Karin Laas and Wallman, {Johan K.} and {van de Sande}, Marleen and Provan, {Sella Aarrestad} and Isabel Castrejon and Jakub Zavada and Corina Mogosan and Nissen, {Michael J.} and Loft, {Anne Gitte} and Anabela Barcelos and Yesim Erez and Pirkmajer, {Katja Perdan} and Gerdur Grondal and Jones, {Gareth T.} and Hokkanen, {Anna Mari} and Chimenti, {Maria Sole} and Sigrid Vorobjov and Giuseppe, {Daniela Di} and Kvien, {Tore K.} and Lucia Otero-Varela and {van der Horst-Bruinsma}, Irene and Hetland, {Merete Lund} and {\O}rnbjerg, {Lykke Midtb{\o}ll}",

note = "Funding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in routine care? Annals of the Rheumatic Diseases 2023;82:606-607. This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2024.",

year = "2024",

month = jul,

day = "24",

doi = "10.1136/rmdopen-2024-004166",

language = "English",

volume = "10",

journal = "RMD Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "3",

}

Christiansen, SN, Rasmussen, SH, Ostergaard, M, Pons, M, Michelsen, B, Pavelka, K, Codreanu, C, Ciurea, A, Glintborg, B, Santos, MJ, Sari, I, Rotar, Z, Gudbjornsson, B, Macfarlane, GJ, Relas, H, Iannone, F, Laas, K, Wallman, JK, van de Sande, M, Provan, SA, Castrejon, I, Zavada, J, Mogosan, C, Nissen, MJ, Loft, AG, Barcelos, A, Erez, Y, Pirkmajer, KP, Grondal, G, Jones, GT, Hokkanen, AM, Chimenti, MS, Vorobjov, S, Giuseppe, DD, Kvien, TK, Otero-Varela, L, van der Horst-Bruinsma, I, Hetland, ML & Ørnbjerg, LM 2024, 'Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study', RMD Open, vol. 10, no. 3, e004166. https://doi.org/10.1136/rmdopen-2024-004166

TY - JOUR

T1 - Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis

T2 - a European routine-care observational study

AU - Christiansen, Sara Nysom

AU - Rasmussen, Simon Horskjær

AU - Ostergaard, Mikkel

AU - Pons, Marion

AU - Michelsen, Brigitte

AU - Pavelka, Karel

AU - Codreanu, Catalin

AU - Ciurea, Adrian

AU - Glintborg, Bente

AU - Santos, Maria Jose

AU - Sari, Ismail

AU - Rotar, Ziga

AU - Gudbjornsson, Bjorn

AU - Macfarlane, Gary J.

AU - Relas, Heikki

AU - Iannone, Florenzo

AU - Laas, Karin

AU - Wallman, Johan K.

AU - van de Sande, Marleen

AU - Provan, Sella Aarrestad

AU - Castrejon, Isabel

AU - Zavada, Jakub

AU - Mogosan, Corina

AU - Nissen, Michael J.

AU - Loft, Anne Gitte

AU - Barcelos, Anabela

AU - Erez, Yesim

AU - Pirkmajer, Katja Perdan

AU - Grondal, Gerdur

AU - Jones, Gareth T.

AU - Hokkanen, Anna Mari

AU - Chimenti, Maria Sole

AU - Vorobjov, Sigrid

AU - Giuseppe, Daniela Di

AU - Kvien, Tore K.

AU - Otero-Varela, Lucia

AU - van der Horst-Bruinsma, Irene

AU - Hetland, Merete Lund

AU - Ørnbjerg, Lykke Midtbøll

N1 - Funding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in routine care? Annals of the Rheumatic Diseases 2023;82:606-607. This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © Author(s) (or their employer(s)) 2024.

PY - 2024/7/24

Y1 - 2024/7/24

N2 - Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

AB - Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

KW - Ankylosing

KW - Epidemiology

KW - Pain

KW - Patient Reported Outcome Measures

KW - Spondylitis

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85199661747&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2024-004166

DO - 10.1136/rmdopen-2024-004166

M3 - Article

C2 - 39053949

AN - SCOPUS:85199661747

SN - 2044-6055

VL - 10

JO - RMD Open

JF - RMD Open

IS - 3

M1 - e004166

ER -

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Abstract

Keywords

Access to Document

Other files and links

Cite this